NEW YORK (GenomeWeb) – Myriad Genetics will be ION Solutions' preferred partner for providing hereditary cancer genetic testing to its member practices, the firms announced today.
ION Solutions is an organization under AmerisourceBergen that provides expertise, technologies, and resources to more than half the community-based oncology practices in the US. Myriad markets MyRisk Hereditary Cancer, a 28-gene panel that assesses whether patients have an increased risk for eight cancers.
"This partnership will advance the organizations' shared goals of providing accurate and comprehensive hereditary cancer test results and service to community oncologists and their patients," ION said in a statement.
In 2014, ION announced a similar preferred partner arrangement with Foundation Medicine in an effort to bring comprehensive genomic profiling services to community oncologists with the FoundationOne and FoundationOne Heme tests.